Abiologics

Abiologics is a developer of biotechnology companies planning to revolutionize the medical field by developing a new type of biologic called synthetic peptides. The company’s platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to computationally design and chemically synthesize supernatural biologics, enabling pharmaceutical and biotechnology clients to effectively bring life-saving treatments to patients. The company is pioneering a new class of supernatural and programmable biologics called Synteins™. The Abiologics platform utilizes state-of-the-art generative artificial intelligence and high-throughput chemical protein synthesis to create Synteins™ with robust and desirable pharmacological properties, redefining what therapeutic agents can achieve for patients across a range of disease areas.